A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germin (Q34854106)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germin |
scientific article |
Statements
1 reference
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germin (English)
1 reference
G Daugaard
1 reference
I Skoneczna
1 reference
N Aass
1 reference
R De Wit
1 reference
M De Santis
1 reference
H Dumez
1 reference
S Marreaud
1 reference
L Collette
1 reference
J R G Lluch
1 reference
C Bokemeyer
1 reference
H J Schmoll
1 reference
8 November 2010
1 reference
1 reference
Identifiers
1 reference